Systemic Immune Response Induced by Oxaliplatin-Based Neoadjuvant Therapy Favours Survival Without Metastatic Progression in High-Risk Rectal Cancer

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0085-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

High Level of Circulating Vitamin D During Neoadjuvant Therapy May Lower Risk of Metastatic Progression in High-Risk Rectal Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Neoadjuvant Systemic Therapy in Breast Cancer

2012English

MRI‑based Neoadjuvant Therapy Indication in Middle and Low Rectal Cancer

Bratislava Medical Journal
2019English

Systemic Treatment in Recurrent and Metastatic Unresectable Rectal Cancer

2011English

Total Neoadjuvant Treatment of Locally Advanced Rectal Cancer With High Risk Factors in Slovenia

Radiology and Oncology
Nuclear MedicineRadiologyImagingOncology
2019English

MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response After Neoadjuvant Therapy

Radiology
Nuclear MedicineRadiologyImaging
2018English

Total Neoadjuvant Therapy for Rectal Cancer: An Emerging Option

Cancer
Cancer ResearchOncology
2017English

Pretreatment Immune Status Correlates With Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients

Cancer immunology research
Cancer ResearchImmunology
2016English

MRI-Based Radiomics Predicts Tumor Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Frontiers in Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy